Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder

被引:2
|
作者
Wang, Liang [1 ]
Tan, Hongmei [1 ]
Huang, Wenjuan [1 ]
ZhangBao, Jingzi [1 ]
Chang, Xuechun [1 ]
Zhou, Lei [1 ]
Lu, Chuanzhen [1 ]
Wang, Min [2 ]
Lu, Jiahong [1 ]
Zhao, Chongbo [1 ]
Quan, Chao [1 ]
机构
[1] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Neurol, 12 Wulumuqi Rd Mid, Shanghai 200040, Peoples R China
[2] Fudan Univ, Dept Ophthalmol & Vis Sci, Eye & ENT Hosp, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
Tacrolimus; Neuromyelitis optica spectrum disorder; Risk factor; DOUBLE-BLIND; MULTICENTER; EFFICACY; SAFETY; SATRALIZUMAB; FK506;
D O I
10.1016/j.msard.2020.102707
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The value of tacrolimus (TAC) in neuromyelitis optica spectrum disorder (NMOSD) has not been fully demonstrated. In this study, we aimed to explore the effectiveness and safety of low-dose TAC in treating NMOSD. Methods: Patients with NMOSD taking low-dose TAC were retrospectively collected. We compared the annualized relapse rate (ARR) before and after the initiation of TAC. Cox proportional hazards model was used to identify the risk factors of relapse during TAC treatment with their hazard ratio (HR). The effectiveness and safety of TAC were also compared with a group of patients on mycophenolate mofetil (MMF). Results: A total of 42 NMOSD patients taking TAC were included, with the administered dose of 1-3mg/d. The ARR (1, 0-3) after the initiation of TAC decreased significantly compared to those before TAC treatment (0, 0-2, p < 0.001). The most common adverse events (AEs) observed included alopecia (23.8%), tremor (16.7%) and elevated blood glucose (11.9%). Multivariate Cox proportional hazards model exhibited that patients with higher baseline ARR (HR: 1.77, 0.76-4.16) and Expanded Disability Status Scale (EDSS) score (HR: 1.79, 1.20-2.68) were at a higher risk for relapse during TAC treatment (p = 0.188 and 0.004, respectively). We did not observe significant difference between TAC-treated and MMF-treated patients regarding the risk of relapse (p = 0.323). Conclusion: Low-dose TAC was an effective and tolerable choice in treating NMOSD.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Low-dose Rituximab therapy for neuromyelitis optica spectrum disorders
    Novo, A.
    Correia, I.
    Marques, I.
    Batista, S.
    Sousa, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 542 - 542
  • [2] Clinical course, safety of low-dose rituximab for vietnameses patients with neuromyelitis optica spectrum disorder
    Le, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 83 - 83
  • [3] Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
    Chen, Bo
    Wu, Qian
    Ke, Gaotan
    Bu, Bitao
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [4] Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
    Bo Chen
    Qian Wu
    Gaotan Ke
    Bitao Bu
    [J]. Scientific Reports, 7
  • [5] The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China
    Chen, Hongxi
    Zhang, Yan
    Shi, Ziyan
    Feng, Huiru
    Yao, Shaoli
    Xie, Jinglu
    Zhou, Hongyu
    [J]. CLINICAL NEUROPHARMACOLOGY, 2016, 39 (02) : 81 - 87
  • [6] Neuromyelitis Optica Spectrum Disorder
    Wingerchuk, Dean M.
    Lucchinetti, Claudia F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (07): : 631 - 639
  • [7] Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report
    Lehrieder, Dominik
    Zapantis, Nikolaos
    Pham, Mirko
    Schuhmann, Michael Klaus
    Haarmann, Axel
    [J]. FRONTIERS IN NEUROLOGY, 2023, 14
  • [8] Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder
    Zhang, Chengyi
    Liu, Rui
    Gao, Bin
    Li, Ting
    Wang, Huabing
    Song, Tian
    Ma, Yuetao
    Xu, Wangshu
    Liu, Yun
    Zhang, Xinghu
    Tian, De-Cai
    Yang, Chunsheng
    Shi, Kaibin
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2024, 387
  • [9] Neuromyelitis optica spectrum disorder and menstruation
    Badihian, Sheruin
    Manouchehri, Navid
    Mirmosayyeb, Omid
    Ashtari, Fereshteh
    Shaygannejad, Vahid
    [J]. REVUE NEUROLOGIQUE, 2018, 174 (10) : 716 - 721
  • [10] Neuromyelitis optica spectrum disorder: an overview
    Ramakrishnan, Pooja
    Nagarajan, Devipriya
    [J]. ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2020, 80 (03) : 256 - 272